High-Density Lipoprotein-Targeted Therapies for Heart Failure
The main and common constituents of high-density lipoproteins (HDLs) are apolipoprotein A-I, cholesterol, and phospholipids. Biochemical heterogeneity of HDL particles is based on the variable presence of one or more representatives of at least 180 proteins, 200 lipid species, and 20 micro RNAs. HDL...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/8/12/620 |
| _version_ | 1797544515398008832 |
|---|---|
| author | Mudit Mishra Bart De Geest |
| author_facet | Mudit Mishra Bart De Geest |
| author_sort | Mudit Mishra |
| collection | DOAJ |
| description | The main and common constituents of high-density lipoproteins (HDLs) are apolipoprotein A-I, cholesterol, and phospholipids. Biochemical heterogeneity of HDL particles is based on the variable presence of one or more representatives of at least 180 proteins, 200 lipid species, and 20 micro RNAs. HDLs are circulating multimolecular platforms that perform divergent functions whereby the potential of HDL-targeted interventions for treatment of heart failure can be postulated based on its pleiotropic effects. Several murine studies have shown that HDLs exert effects on the myocardium, which are completely independent of any impact on coronary arteries. Overall, HDL-targeted therapies exert a direct positive lusitropic effect on the myocardium, inhibit the development of cardiac hypertrophy, suppress interstitial and perivascular myocardial fibrosis, increase capillary density in the myocardium, and prevent the occurrence of heart failure. In four distinct murine models, HDL-targeted interventions were shown to be a successful treatment for both pre-existing heart failure with reduced ejection fraction (HFrEF) and pre-existing heart failure with preserved ejection fraction (HFrEF). Until now, the effect of HDL-targeted interventions has not been evaluated in randomized clinical trials in heart failure patients. As HFpEF represents an important unmet therapeutic need, this is likely the preferred therapeutic domain for clinical translation. |
| first_indexed | 2024-03-10T14:01:37Z |
| format | Article |
| id | doaj.art-ff199fd2bbba44a4ae1ef0cbfc5298ed |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T14:01:37Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-ff199fd2bbba44a4ae1ef0cbfc5298ed2023-11-21T01:09:30ZengMDPI AGBiomedicines2227-90592020-12-0181262010.3390/biomedicines8120620High-Density Lipoprotein-Targeted Therapies for Heart FailureMudit Mishra0Bart De Geest1Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Catholic University of Leuven, 3000 Leuven, BelgiumCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Catholic University of Leuven, 3000 Leuven, BelgiumThe main and common constituents of high-density lipoproteins (HDLs) are apolipoprotein A-I, cholesterol, and phospholipids. Biochemical heterogeneity of HDL particles is based on the variable presence of one or more representatives of at least 180 proteins, 200 lipid species, and 20 micro RNAs. HDLs are circulating multimolecular platforms that perform divergent functions whereby the potential of HDL-targeted interventions for treatment of heart failure can be postulated based on its pleiotropic effects. Several murine studies have shown that HDLs exert effects on the myocardium, which are completely independent of any impact on coronary arteries. Overall, HDL-targeted therapies exert a direct positive lusitropic effect on the myocardium, inhibit the development of cardiac hypertrophy, suppress interstitial and perivascular myocardial fibrosis, increase capillary density in the myocardium, and prevent the occurrence of heart failure. In four distinct murine models, HDL-targeted interventions were shown to be a successful treatment for both pre-existing heart failure with reduced ejection fraction (HFrEF) and pre-existing heart failure with preserved ejection fraction (HFrEF). Until now, the effect of HDL-targeted interventions has not been evaluated in randomized clinical trials in heart failure patients. As HFpEF represents an important unmet therapeutic need, this is likely the preferred therapeutic domain for clinical translation.https://www.mdpi.com/2227-9059/8/12/620high-density lipoproteinsheart failurecardiac hypertrophymyocardial fibrosisgene therapynanoparticles |
| spellingShingle | Mudit Mishra Bart De Geest High-Density Lipoprotein-Targeted Therapies for Heart Failure Biomedicines high-density lipoproteins heart failure cardiac hypertrophy myocardial fibrosis gene therapy nanoparticles |
| title | High-Density Lipoprotein-Targeted Therapies for Heart Failure |
| title_full | High-Density Lipoprotein-Targeted Therapies for Heart Failure |
| title_fullStr | High-Density Lipoprotein-Targeted Therapies for Heart Failure |
| title_full_unstemmed | High-Density Lipoprotein-Targeted Therapies for Heart Failure |
| title_short | High-Density Lipoprotein-Targeted Therapies for Heart Failure |
| title_sort | high density lipoprotein targeted therapies for heart failure |
| topic | high-density lipoproteins heart failure cardiac hypertrophy myocardial fibrosis gene therapy nanoparticles |
| url | https://www.mdpi.com/2227-9059/8/12/620 |
| work_keys_str_mv | AT muditmishra highdensitylipoproteintargetedtherapiesforheartfailure AT bartdegeest highdensitylipoproteintargetedtherapiesforheartfailure |